journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/30419129/performance-of-a-multigene-genomic-classifier-in-thyroid-nodules-with-indeterminate-cytology-a-prospective-blinded-multicenter-study
#1
David L Steward, Sally E Carty, Rebecca S Sippel, Samantha Peiling Yang, Julie A Sosa, Jennifer A Sipos, James J Figge, Susan Mandel, Bryan R Haugen, Kenneth D Burman, Zubair W Baloch, Ricardo V Lloyd, Raja R Seethala, William E Gooding, Simion I Chiosea, Cristiane Gomes-Lima, Robert L Ferris, Jessica M Folek, Raheela A Khawaja, Priya Kundra, Kwok Seng Loh, Carrie B Marshall, Sarah Mayson, Kelly L McCoy, Min En Nga, Kee Yuan Ngiam, Marina N Nikiforova, Jennifer L Poehls, Matthew D Ringel, Huaitao Yang, Linwah Yip, Yuri E Nikiforov
Importance: Approximately 20% of fine-needle aspirations (FNA) of thyroid nodules have indeterminate cytology, most frequently Bethesda category III or IV. Diagnostic surgeries can be avoided for these patients if the nodules are reliably diagnosed as benign without surgery. Objective: To determine the diagnostic accuracy of a multigene classifier (GC) test (ThyroSeq v3) for cytologically indeterminate thyroid nodules. Design, Setting, and Participants: Prospective, blinded cohort study conducted at 10 medical centers, with 782 patients with 1013 nodules enrolled...
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30419106/palliative-care
#2
Timothy J Brown, Thomas J Smith, Arjun Gupta
No abstract text is available yet for this article.
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30419105/is-precision-medicine-an-oxymoron
#3
S Gail Eckhardt, Christopher Lieu
No abstract text is available yet for this article.
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30419088/comparison-of-local-control-of-brain-metastases-with-stereotactic-radiosurgery-vs-surgical-resection-a-secondary-analysis-of-a-randomized-clinical-trial
#4
Thomas M Churilla, Imran H Chowdhury, Elizabeth Handorf, Laurence Collette, Sandra Collette, Yanqun Dong, Brian M Alexander, Martin Kocher, Riccardo Soffietti, Elizabeth B Claus, Stephanie E Weiss
Importance: Brain metastases are a common source of morbidity for patients with cancer, and limited data exist to support the local therapeutic choice between surgical resection and stereotactic radiosurgery (SRS). Objective: To evaluate local control of brain metastases among patients treated with SRS vs surgical resection within the European Organization for the Research and Treatment of Cancer (EORTC) 22952-26001 phase 3 trial. Design, Setting, and Participants: This unplanned, exploratory analysis of the international, multi-institutional randomized clinical trial EORTC 22952-26001 (conducted from 1996-2007) was performed from February 9, 2017, through July 25, 2018...
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30419081/moving-precision-oncology-forward-amid-myths-and-misconceptions
#5
Balkees Abderrahman, V Craig Jordan
No abstract text is available yet for this article.
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30419080/moving-precision-oncology-forward-amid-myths-and-misconceptions-reply
#6
John Marquart, Emerson Y Chen, Vinay Prasad
No abstract text is available yet for this article.
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30419079/moving-precision-oncology-forward-amid-myths-and-misconceptions
#7
Filip Janku, Kenneth R Hess, Timothy A Yap
No abstract text is available yet for this article.
November 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383184/safety-and-efficacy-of-durvalumab-with-or-without-tremelimumab-in-patients-with-pd-l1-low-negative-recurrent-or-metastatic-hnscc-the-phase-2-condor-randomized-clinical-trial
#8
Lillian L Siu, Caroline Even, Ricard Mesía, Eva Remenar, Amaury Daste, Jean-Pierre Delord, Jürgen Krauss, Nabil F Saba, Lisle Nabell, Neal E Ready, Irene Braña, Nuria Kotecki, Dan P Zandberg, Jill Gilbert, Hisham Mehanna, Marcelo Bonomi, Anthony Jarkowski, Giovanni Melillo, Jon M Armstrong, Sophie Wildsmith, Jérôme Fayette
Importance: Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is unknown whether dual blockade can potentiate antitumor activity without compromising safety in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) and low or no PD-L1 tumor cell expression. Objective: To assess safety and objective response rate of durvalumab combined with tremelimumab...
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383169/hypofractionated-nodal-irradiation-for-breast-cancer-a-case-for-caution
#9
Vincent Vinh-Hung, Nam P Nguyen, Claire Verschraegen
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383153/white-noise
#10
Mousumi Banerjee
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383141/focus-on-the-number-of-radiation-oncology-trials-or-on-clinical-relevance
#11
Cyrus Chargari, Christophe Massard, Eric Deutsch
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383140/efficacy-and-tolerability-of-5-year-adjuvant-imatinib-treatment-for-patients-with-resected-intermediate-or-high-risk-primary-gastrointestinal-stromal-tumor-the-persist-5-clinical-trial
#12
Chandrajit P Raut, N Joseph Espat, Robert G Maki, Dejka M Araujo, Jonathan Trent, Toni Faith Williams, D Das Purkayastha, Ronald P DeMatteo
Importance: Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of therapy is unknown. Objective: To determine whether adjuvant treatment for primary GIST with imatinib for 5 years is tolerable and efficacious. Design, Setting, and Participants: This prospective, single-arm, phase 2 clinical trial (Postresection Evaluation of Recurrence-free Survival for Gastrointestinal Stromal Tumors With 5 Years of Adjuvant Imatinib [PERSIST-5]) included adult patients with primary GIST (expressing KIT) at 21 US institutions who underwent a macroscopically complete resection and were at intermediate or high risk of recurrence, defined as primary GIST at any site measuring 2 cm or larger with 5 or more mitoses per 50 high-power field or nongastric primary GIST measuring 5 cm or larger...
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383137/cancer-risk-estimates-for-study-of-multiple-gene-testing-after-diagnosis-of-breast-cancer
#13
Steven A Narod
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383135/early-adoption-of-biosimilar-growth-factors-in-supportive-cancer-care
#14
Xiaoxue Chen, Abiy Agiro, John Barron, David Debono, Michael Fisch
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383131/cancer-risk-estimates-for-study-of-multiple-gene-testing-after-diagnosis-of-breast-cancer-reply
#15
Allison W Kurian, Steven J Katz
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383128/assessment-of-reported-trial-characteristics-rate-of-publication-and-inclusion-of-mandatory-biopsies-of-research-biopsies-in-clinical-trials-in-oncology
#16
Christine M Parseghian, Alda L Tam, James Yao, Joe Ensor, Lee M Ellis, Kanwal Raghav, Michael J Overman
Importance: Research biopsies are frequently incorporated within clinical trials in oncology and are often a mandatory requirement for trial enrollment. However, limited information is available regarding the extent and completeness of research biopsy reporting. Objectives: To determine the rate of research biopsy reporting for clinical trials registered in ClinicalTrials.gov and determine the clinical trial factors that correlated with research biopsy reporting...
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30383125/focus-on-the-number-of-radiation-oncology-trials-or-on-clinical-relevance-reply
#17
Xu Liu, Quynh Thu Le, Jun Ma
No abstract text is available yet for this article.
November 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30422162/failure-to-accurately-disclose-conflicts-of-interest-in-articles-published-in-jama-oncology
#18
José Baselga
No abstract text is available yet for this article.
October 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30422161/missing-conflict-of-interest-disclosure
#19
(no author information available yet)
No abstract text is available yet for this article.
October 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/30422243/survival-outcomes-in-patients-with-previously-untreated-braf-wild-type-advanced-melanoma-treated-with-nivolumab-therapy-three-year-follow-up-of-a-randomized-phase-3-trial
#20
Paolo A Ascierto, Georgina V Long, Caroline Robert, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Kerry J Savage, Micaela M Hernberg, Celeste Lebbé, Julie Charles, Catalin Mihalcioiu, Vanna Chiarion-Sileni, Cornelia Mauch, Francesco Cognetti, Lars Ny, Ana Arance, Inge Marie Svane, Dirk Schadendorf, Helen Gogas, Abdel Saci, Joel Jiang, Jasmine Rizzo, Victoria Atkinson
Importance: This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors. Objective: To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. Design, Setting, and Participants: This follow-up of a randomized phase 3 trial analyzed 3-year overall survival data from the randomized, controlled, double-blind CheckMate 066 phase 3 clinical trial...
October 25, 2018: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"